Standard Life Aberdeen plc lessened its holdings in shares of Cigna Corp (NYSE:CI) by 1.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 171,726 shares of the health services provider’s stock after selling 2,209 shares during the quarter. Standard Life Aberdeen plc’s holdings in Cigna were worth $35,116,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC grew its holdings in Cigna by 16.7% during the 4th quarter. FMR LLC now owns 15,414,573 shares of the health services provider’s stock valued at $3,152,127,000 after buying an additional 2,206,181 shares in the last quarter. Marshall Wace North America L.P. lifted its holdings in shares of Cigna by 468.8% in the fourth quarter. Marshall Wace North America L.P. now owns 894,988 shares of the health services provider’s stock worth $183,014,000 after buying an additional 737,631 shares in the last quarter. Sanders Capital LLC lifted its holdings in shares of Cigna by 13.5% in the fourth quarter. Sanders Capital LLC now owns 5,317,641 shares of the health services provider’s stock worth $1,209,761,000 after buying an additional 631,998 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Cigna by 41.1% during the fourth quarter. Farallon Capital Management LLC now owns 1,500,000 shares of the health services provider’s stock worth $306,735,000 after acquiring an additional 437,210 shares during the last quarter. Finally, Owl Creek Asset Management L.P. bought a new position in shares of Cigna during the third quarter worth $63,720,000. 89.88% of the stock is currently owned by institutional investors.
CI traded up $12.72 on Thursday, hitting $169.54. The company had a trading volume of 4,059,302 shares, compared to its average volume of 2,756,040. The company has a market cap of $58.32 billion, a PE ratio of 12.62, a PEG ratio of 0.70 and a beta of 0.72. Cigna Corp has a 12-month low of $118.50 and a 12-month high of $224.64. The company has a quick ratio of 0.64, a current ratio of 0.64 and a debt-to-equity ratio of 0.70. The business’s fifty day simple moving average is $191.41 and its 200 day simple moving average is $186.35.
The business also recently announced an annual dividend, which will be paid on Thursday, April 9th. Stockholders of record on Tuesday, March 10th will be given a dividend of $0.04 per share. This represents a dividend yield of 0.02%. The ex-dividend date of this dividend is Monday, March 9th. Cigna’s dividend payout ratio is currently 0.23%.
CI has been the topic of a number of research reports. Wells Fargo & Co downgraded shares of Cigna from a “market perform” rating to an “underperform” rating and set a $181.00 price target on the stock. in a report on Wednesday, December 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $255.00 target price (up from $245.00) on shares of Cigna in a report on Thursday, February 6th. Citigroup lifted their target price on Cigna from $221.00 to $263.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Evercore ISI started coverage on Cigna in a research report on Friday, February 7th. They issued a “hold” rating and a $230.00 target price on the stock. Finally, SunTrust Banks reissued a “buy” rating and set a $280.00 price target on shares of Cigna in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, two have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $238.65.
In related news, EVP Steven B. Miller sold 7,145 shares of Cigna stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $212.15, for a total transaction of $1,515,811.75. Following the completion of the transaction, the executive vice president now directly owns 32,071 shares of the company’s stock, valued at approximately $6,803,862.65. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Matthew G. Manders sold 3,969 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $182.85, for a total transaction of $725,731.65. Following the transaction, the insider now owns 46,018 shares in the company, valued at $8,414,391.30. The disclosure for this sale can be found here. In the last three months, insiders have sold 74,397 shares of company stock worth $14,922,093. Corporate insiders own 0.90% of the company’s stock.
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
Read More: What is the Rule of 72?
Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Corp (NYSE:CI).
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.